Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
02 Novembre 2023 - 2:05PM
Business Wire
-- New and Updated Data from Ongoing Phase 2
Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for
Podium Presentation --
Omeros Corporation (Nasdaq: OMER) today announced that two
abstracts directed to OMS906, Omeros’ investigational inhibitor of
MASP-3, the key activator of the alternative pathway of complement,
will be presented at the 65th Annual Meeting of the American
Society of Hematology (ASH), to be held December 9-12, 2023 in San
Diego.
Both abstracts were published today and are now available on the
ASH website at www.hematology.org. Details of the congress
presentations are found below.
OMS906, a Novel Alternative Pathway MASP-3
Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in
Treatment-Naïve PNH Patients (Abstract #573) Session Name: 508.
Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy
from Clinical Trials Date: Sunday, December 10, 2023 Podium
Presentation Time: 5:00 p.m. PT Location: San Diego Convention
Center, Room 7
Alternative Pathway MASP-3 Inhibitor
OMS906 Effectively and Potently Inhibits Complement-Mediated
Hemolysis in Preclinical Models Mechanistically Similar to
Paroxysmal Nocturnal Hemoglobinuria (Abstract #4082) Session
Name: 508. Bone Marrow Failure: Acquired: Poster III Date: Monday,
December 11, 2023 Presentation Time: 6:00 p.m. - 8:00 p.m. PT
Location: San Diego Convention Center, Halls G-H
The presentation materials associated with each abstract will be
made available on Omeros’ website at www.omeros.com following the
congress presentations.
About OMS906
OMS906 is an investigational human monoclonal antibody targeting
mannan-binding lectin-associated serine protease-3 (MASP-3), the
key activator of the complement system’s alternative pathway. The
complement system plays a central role in inflammation and becomes
activated as a result of tissue damage or microbial infection.
Responsible for the conversion of pro-complement factor D to
complement factor D, MASP-3 is believed to be the premier target in
the alternative pathway – it has the lowest native circulating
level and low relative clearance compared to the other alternative
pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition
leaves intact the lytic arm of the classical pathway, important for
fighting infection. Also, unlike other components of the
alternative pathway, MASP-3 is believed not to be an acute phase
reactant, which could provide a significant advantage to MASP-3
inhibitors, like OMS906, over other alternative pathway inhibitors.
MASP-3 inhibitors are thought to have preventive or therapeutic
effects across a broad range of diseases including paroxysmal
nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS),
atypical HUS, traumatic brain injury, arthritis, wet age-related
macular degeneration, ischemia-reperfusion injury,
transplant-related complications and other immune-related
disorders.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
(BLA) pending before FDA for the treatment of hematopoietic stem
cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing in clinical programs for paroxysmal nocturnal
hemoglobinuria (PNH), complement 3 (C3) glomerulopathy. Funded by
the National Institute on Drug Abuse, Omeros’ lead
phosphodiesterase 7 (PDE7) inhibitor OMS527 is in clinical
development for the treatment of cocaine use disorder (CUD) and is
also being developed as a therapeutic for other addictions as well
as for a major complication of treatment for movement disorders.
Omeros also is advancing a broad portfolio of novel immuno-oncology
programs comprised of two cellular and three molecular platforms.
For more information about Omeros and its programs, visit
www.omeros.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102559762/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Giu 2023 a Giu 2024